Reuters logo
BRIEF-Revance provides update on mid-stage study of heel pain drug
May 1, 2017 / 11:44 AM / 5 months ago

BRIEF-Revance provides update on mid-stage study of heel pain drug

May 1 (Reuters) - Revance Therapeutics Inc-

* Revance provides update on phase 2 program for RT002 injectable in the management of plantar fasciitis

* Revance Therapeutics Inc - revance expects to report topline results from phase 2 study in q4 of 2017

* Revance Therapeutics Inc - study protocol has been submitted to U.S. Food and drug administration and is scheduled to post on clintrials.gov this week

* Revance Therapeutics- expanding program investigating use of daxibotulinumtoxina for injection from a single center to a multi-center study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below